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PENILAIAN KESAN MANFAAT VITAMIN C DAN TEH HIJAU 
POLIFENOL ANTIOKSIDAN DALAM TIKUS NORMOTENSIF DAN 
HIPERTENSI DENGAN ATAU TANPA KEGAGALAN GINJAL 
 
ABSTRAK 
Tekanan oksidatif ialah salah satu daripada factor-faktor di dalam patogenesis 
hipertensif dengan atau tanpa kegagalan ginjal (RF). Vitamin C (VIT. C) dan teh 
hijau polifenol merupakan vitamin C  dan GTPP agen dietik yang mempunyai 
tindakan-tindakan berfaedah yang berlainan di dalam badan manusia. Kajian ini 
bertujuan untuk menilai faedah VIT. C dan GTPP di dalam tikus normotensif dan 
hipertensif dengan atau tanpa kegagalan ginjal. Kegagalan ginjal telah dicetuskan di 
dalam tikus normotensive dan hipertensif dengan suntikan cisplatin dos tunggal 
secara intraperitoneal pada hari pertama di dalam kajian ini (n=6 jantan). Rawatan 
dengan Vitamin C telah dilakukan pada dua dos iaitu dos rendah (VIT. C-LD; 
500mg/day, secara oral) dan dos tinggi VIT. C (VIT. C-HD 1000mg/day, secara 
oral). Tatkala, dos rendah GTPP (GTPP-LD; 500mg/kg, secara oral) dan dos tinggi 
GTPP (GTPP-HD; 1000mg/kg, secara oral) telah dimulakan dari hari ke-7 sehingga 
hari ke-28 eksperimen. Tekanan darah bukan invasif (NIBP) telah diukur hanya pada 
hari ke-0 dan kajian metabolik telah dijalankan pada hari ke-0, 7, dan 28. Haiwan 
telah telah dianestetik untuk mengukur tekanan darah, hemodinamik ginjal, penanda 
oksidatif dan antioksidan di dalam plasma pada hari ke-29. Induksi kegagalan ginjal 
telah disahkan melalui asai biokimia untuk parameter fungi ginjal dan telah disahkan 
lagi dengan pemeriksaan histopatologi dengan menggunakan asai hematoxylin dan 
eosin (H & E). Asai kas protein telah dijalankan dengan menggunakan reagen asid 
berkala kerja giliran (PAS). Satu nilai kebarangkalian kurang daripada 5 % telah 
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diset untuk mempertimbangkan perbezaan signifikan parameter sistemik 
hemodinamik seperti tekanan darah sistolik (SBP), tekanan darah diastolic (DBP) 
dan min tekanan arteri (MAP) yang telah menunjukkan bahawa SHR+RF+VIT. C-
HD, SHR+RF+GTPP-LD dan SHR+RF+GTPP-HD telah berkurang secara 
signifikan (semua P<0.05) apabila dibandingkan dengan SHR. Min tekanan arteri 
VIT. C-HD-RF telah berkurang secara signifikan (semua P<0.05) apabila 
dibandingkan dengan WKY-NRF dan VIT. C-HD-NRF. Data hemodinamik sistemik 
telah menunjukkan bahawa VIT. C-HD, GTPP-LD dan GTPP-HD mempunyai kesan 
mengurangkan tekanan darah yang signifikan di dalam kumpulan kegagalan ginjal 
SHR. Tambahan pula, aruhan kegagalan ginjal oleh cisplatin telah menunjukkan 
peningkatan tekanan oksidatif dan kekejangan arteri serta pengurangan perfusi darah 
kortikal ginjal yang jelas. Rawatan dengan VIT.C dan GTPP telah meningkatkan 
status antioksidan di dalam plasma, mengurangkan kekejangan arteri  dan 
meningkatkan perfusi darah kortikal ginjal secara signifikan yang mungkin dengan 
meningkatkan kepekatan nitrik oksida dalam plasma di dalam kedua-dua modal 
normotensif dan hipertensif yang mengalami kegagalan ginjal apabila dibandingkan 
dengan kumpulan WKY-RF dan SHR-RF. Fungsi perkumuhan ginjal dan kreatinin 
di dalam plasma  modal-modal kegagalan ginjal normotensif dan hipertensif telah 
meningkat secara signifikan (semua P<0.05) apabila dibandingkan dengan 
kumpulan-kumpulan tersebut yang tidak mengalami kegagalan ginjal. Rawatan 
dengan dos VIT. C and GTPP yang berlainan dalam modal-modal normotensif dan 
hipertensif yang mengalami kegagalan ginjal telah terbalikkan kerosakan yang 
disebabkan oleh cisplatin dan  pulihkan keupayaan penyerapan semula ginjal yang 
telah dipamerkan melalui pengurangan fungsi perkumuhan ginjal, pengurangan tahap 
kreatinin dalam plasma dan peningkatan nitrik oksida. Pemulihan fungsi perkumuhan 
dan penyerapan ginjal dengan rawatan VIT. C dan GTPP telah disahkan melalui 
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histopatologi ginjal dengan menggunakan reagen hematoxylin dan eosin (H&E) dan 
asid berkala kerja giliran (PAS). Pendapatan ini mencadangkan secara kolektif 
bahawa potensi antioksidan oleh VIT. C and GTPP merupakan pengantara vascular 
dan kesan perlindungan ginjal melalui peningkatan tahap NO di dalam modal 
normotensive dan hipertensif yang mengalami kegagalan ginjal. 
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EVALUATION OF BENEFICIAL EFFECTS OF VITAMIN C AND GREEN 
TEA POLYPHENOL ANTIOXIDANT IN NORMOTENSIVE AND 
HYPERTENSIVE RATS WITH OR WITHOUT RENAL FAILURE 
 
ABSTRACT 
Oxidative stress is one of the factors in the pathogenesis of hypertension with 
or without renal failure (RF). Vitamin C (VIT. C) and green tea polyphenol (GTPP) 
are the VIT. C and GTPP dietary agents which have different beneficial actions in 
human body.  The present study aimed to evaluate the beneficial of VIT. C and 
GTPP in normotensive rats and hypertensive rats with or without renal failure. Renal 
failure was induced in normotensive and hypertensive rats by a single dose of 
intraperitoneal injection of cisplatin on day 1 in this study (n=6 males). Treatment 
with VIT. C was done at both low doses VIT. C-LD; 500mg/day, orally), and VIT. C 
high dose (VIT. C-HD 1000mg/day, orally). While GTPP low dose (GTPP-LD; 
500mg/kg, orally) and GTPP high dose (GTPP-HD; 1000mg/kg, orally) were started 
from day 7 until day 28 of the experiment. Non-invasive blood pressure (NIBP) was 
measured only on day 0   and metabolic studies were performed on days 0, 7, and 28. 
Animals were anaesthetized to measure blood pressure, renal hemodynamics, plasma 
oxidative and antioxidant marker on day 29. Induction of renal failure in both models 
was confirmed by biochemical assays for renal functional parameters and further 
confirmed by histopathological examinations using hematoxylin and eosin assay 
(H&E). Protein cast assays were carried out by using periodic acid-Schiff (PAS) 
reagents. A probability value of less than 5% was set to consider significant 
differences systemic hemodynamic parameters like systolic blood pressure (SBP), 
diastolic blood pressure (DBP) and mean arterial pressure (MAP) have shown that 
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SHR+RF+VIT. C-HD, SHR+RF+GTPP-LD and SHR+RF+GTPP-HD are 
significantly reduced (all P<0.05) when compared to SHR. VIT. C-HD-RF 
significantly reduced (all P<0.05) mean arterial pressure (MAP) when compared to 
that of WKY-NRF and (VIT. C-HD-NRF. Systemic hemodynamic data showed that 
VIT. C-HD, GTPP-LD and GTPP-HD have significant blood pressure lowering 
effects in renal failure groups of SHRs. Moreover, cisplatin-induced renal failure rats 
exhibited marked increase in oxidative stress, increased arterial stiffness and reduced 
renal cortical blood perfusion. Treatment with vitamin C (VIT. C) and green tea 
polyphenol (GTPP) significantly increased (all P<0.05) the antioxidant status in 
plasma, reduced the arterial stiffness and increased the renal cortical blood perfusion 
possibly by increasing plasma nitric oxide (NO) concentration of both normotensive 
and hypertensive models of renal failure when compared to WKY-RF and SHR-RF 
group. Renal excretory function and creatinine in the plasma of normotensive and 
hypertensive models of renal failure were significantly increased (all P<0.05) 
compared to their non-renal failure groups. Treatment of normotensive and 
hypertensive models of renal failure with different doses of VIT. C and GTPP 
reversed the damage induced by cisplatin and restored the reabsorption ability of the 
kidney as exhibited by a reduction in the excretory function of the kidney, reduction 
in of creatinine levels in the plasma and elevation of nitric oxide The amelioration of 
renal excretory function and reabsorption due to  VIT. C and GTPP treatment were 
confirmed by histopathology of the kidney using hematoxylin and exotoxin (H&E) 
and Periodic acid-Schiff (PAS) staining. These findings collectively suggest that 
antioxidant potential of VIT. C and GTPP mediates the vascular and renoprotective 
effects through increased NO level in normotensive and hypertensive model of renal 
failure. 
1 
CHAPTER 1 
1. INTRODUCTION 
 
 
1.1       The kidneys 
Kidneys are one of the major organs of primary importance in the urinary as 
well as the cardiovascular system. They not only excrete metabolic wastes from the 
body but also maintain homeostasis. Kidneys selectively excrete these waste 
products from the plasma and sequentially reabsorb some important metabolic 
products during various steps of reabsorption, tubular secretion and urinary 
excretion. Kidneys act as endocrine glands by releasing renin, which ultimately 
regulates blood pressure. It is reported that persistent elevated blood pressure is due 
to improper function of the kidneys (Sattar & Johns, 1994; Applegate, 2000; Schrier 
et al., 2004). 
A pair of kidneys is present on each side of the vertebral column on the 12
th
 
thoracic and 3
rd
 lumbar vertebrae. The appearance of the kidney is bean shaped with 
an indent on the middle part, called the hilum. A cross section of the kidney shows 
that it is made up of cortex and medulla. Both are considered as functional tissues of 
the kidney (Applegate, 2000). 
The nephron is known as the functional unit of kidney. Each kidney contains 
about 12 million nephrons. A nephron comprises of two major parts, the renal 
corpuscle which is a rich network of capillaries called the glomerulus and renal 
tubules which extend into renal corpuscle. Renal tubules are in connection with 
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glomerulus that carries fluid and some waste product through proximal convoluted 
tubules, loop of Henle, and distal convoluted tubules to bladder (Applegate, 2000).      
1.1.1 The glomerulus  
The glomerulus comprises of a rich network of capillaries and a balloon like 
structure known as Bowman‟s capsule. Each glomerulus carries afferent arterioles 
that carry the blood towards glomerulus and efferent arterioles which carry blood 
away from glomerulus. Glomerulus maintains a pressure gradient which is 
responsible for filtration of different substances like creatinine and albumin. Amount 
of fluid which is filtered through glomerulus in one minute is known as glomerular 
filtration rate (GFR) and its normal value is 125ml/min. This is mostly 20 % of renal 
plasma flow (Applegate, 2000a). 
1.1.2 Proximal convoluted tubules 
Proximal convoluted tubule (PCT) is the first part of renal tubules and is 
responsible for reabsorption of 60-70 % of electrolytes like sodium and potassium. 
PCT consists of a convoluted and a straight part (Abdel-Raheem et al., 2010). From 
the PCT, fluid flows to the loop of Henle which descends down to the medulla. Each 
loop of Henle consists of an ascending and a descending part. The descending loop 
of Henle and lower part of the ascending region has thin walls and is therefore called 
the thin segment of loop of Henle, while the upper part of the ascending loop of 
Henle has thick walls and is therefore named as thick segment of the ascending limb 
(Figure 1). At the end of this ascending limb is a plaque like structure called macula 
densa which controls the function of the nephrons. Beyond macula densa, the fluid 
enters into the distal tubules which lie in the renal cortex like the PCT. The distal 
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tubules lead to the collecting tubules, which collectively lead to the formation of the 
collecting duct (Guyton, 1996).  
1.2   Renal hemodynamics 
The total blood flow to the kidneys in an adult of 70 kg is approximately 1100 
mL/min. Although the weight of both kidneys is less than 1% of the total body 
weight, the kidneys receive 20-25% of total cardiac output (5 L/min) (Guyton, 1996; 
Applegate, 2000). The micro vessels in the kidneys have the ability to auto-regulate 
the renal plasma flow. Altered distribution of plasma in kidney may cause changes in 
renal function. Therefore, for normal kidney function, the uniform distribution of 
renal plasma flow is very important (Regan et al., 1995). 
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Figure ‎1.1 Schematic diagrams showing the relationship between blood vessels 
renal tubules (adapted from (Hall, 2010) 
 
1.2.1 Factors influencing renal hemodynamics 
Factors that influence renal hemodynamic are divided into intrinsic and 
extrinsic factors. Intrinsic factors include auto regulation mechanism, renal renin 
angiotensin system, eicosanoid and kidney. Extrinsic pathway includes 
sympathetic nervous system, angiotensin II, vasopressin, dopamine and 
histamine. Besides these intrinsic and extrinsic factors, there are also roles for 
endothelial nitric oxide (NO) and atrial natriuretic peptides (Unwin, 2000).   
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1.2.2 Regulation of vascular tone: Role of endothelium 
Endothelium is a very thin, monolayer of endothelial cells; it is the innermost 
lining of blood and lymphatic vessels. Endothelial cells play a major role in the 
control of vascular tone and vascular homeostasis and thus control blood flow by 
releasing its potent relaxing and contracting factors. Important vascular functions that 
involve endothelial cells include: vasculogenesis, angiogenesis and arteriogenesis, 
inflammation, regulation of blood pressure and apoptosis. Due to its strategic 
position at the blood/tissue interface, it lies in direct contact with various circulating 
factors such as antioxidants, oxidized low-density lipoprotein (LDL), and also pro-
inflammatory cytokines like the tumour necrosis factor (TNF) or interleukins (IL) 
(Cines et al., 1998; Brown & Hu, 2001). Therefore, endothelial dysfunction may be a 
very important hallmark in the pathogenesis of thrombosis and cardiovascular 
diseases (CVD) such as atherosclerosis and hypertension and may thereby lead to 
many damaging processes to vascular cells and the surrounding tissue (Matz & 
Andriantsitohaina, 2003). 
Endothelial cells also play a major role in the regulation of vascular tone by 
releasing vasoconstrictor agents such as endothelin-1 (ET-1), angiotensin II (Ang II) 
and thromboxane A2 (TXA2) (Moncada & Vane, 1978; Furchgott & Zawadzki, 1980; 
Ignarro et al., 1987; Feletou & Vanhoutte, 1988; Luescher & Barton, 1997) and a 
very potent vasodilator agent, nitric oxide (NO) which also acts as a free radical 
scavenger and prostacyclin (PGI2). Both NO and PGI2 exert vasodilator effect on 
blood vessels and inhibit platelet activation. Since NO is released from the 
endothelium, it is also known as endothelium-derived relaxing factor (EDRF). NO is 
biosynthesized from L-arginine by endothelial NO synthase (eNOS) enzyme. It can 
diffuse freely across vascular smooth muscle cells. It exerts its vasorelaxation 
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properties via various pathways including activation of guanylate cyclase enzyme, 
which further leads to the production of cyclic guanosine monophosphate (cGMP).. 
Furthermore, prostacyclin exerts its vasodilator action via (cyclooxygenase (COX), 
also known as prostaglandin H synthase (PGHS) or prostaglandin endoperoxide 
synthase pathway. It is mainly mediated by prostacyclin receptors and intracellular 
peroxisome proliferator-activated receptors (PPAR) beta (Lüscher & Vanhoutte, 
1986).  
1.3  Indices for arterial stiffness 
Cardiovascular diseases have been considered as the leading cause of morbidity 
and mortality in developing countries and cannot be predicted by classical predictors 
alone (Laurent et al., 2001). An increase in arterial stiffness may elevate systolic 
blood pressure (SBP) which ultimately raises the after load. This raised after load 
results in a reduction in the diastolic blood pressure which will modify the coronary 
perfusion (Koen et al., 2011; Safar, 1989). 
Many indices have been introduced to estimate the stiffness of the arteries. In 
1994, the International Society of Hypertension in its meeting decided to postulate an 
interim measurement. None of the method was found to be superior over the other 
and some challenges in measurement and interpretation were faced (O‟Rourke et al., 
2002). In this study pulse wave velocity (PWV) was used as an index for estimation 
of arterial stiffness. Measurement of oxidative stress parameters can give an idea 
about endothelial dysfunction. 
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1.3.1 Pulse wave velocity  
PWV is taken as a marker of arterial stiffness (Sutton-Tyrrell et al., 2005). 
PWV can be defined as the distance travelled (Δx) by the pressure wave divided by 
the time (Δt) taken for the wave to travel that distance. 
PWV = Δx /Δt 
PWV can be measured between two sites of an artery, at a known distance apart 
using 
“
foot to foot” technique of the waveform to calculate the transit time. As shown 
in Figure 1.2 PWV measurement requires only two pressure wave forms recorded 
simultaneously with invasive catheters, or mechanical tonometers applied non-
invasively to the pulse across the skin.  It is considered as a marker of arterial 
stiffness (Wilkinson, et al., 1998; Nichols, 2005). There is a strong correlation 
between PWV and cardiovascular events and both cause mortality (Blacher et al., 
1999; Cruickshank et al., 2002; Laurent et al., 2001). 
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Figure ‎1.2: Schematic illustration of the measurement of pulse wave velocity 
(PWV) in the rat. PWV is the ratio of the distance (D) between the tips of the 2 
catheters and the difference between the time at the minimal values of proximal 
and distal blood pressure. Adapted from (Cosson et al., 2007)  
 
 
1.3.2 Mechanisms of arterial stiffness 
Arterial stiffening or hardening in renal disease involves several mechanisms. 
It occurs as a result of many independent and inter-dependent factors. One of the 
factors which influence greatly in the stiffness of vascular wall is the imbalance 
between collagen and elastin (Zieman et al., 2005).  
Elastin is an important protein responsible for vascular flexibility, however in 
state of inflammation within the body that leads to increased degradation of collagen 
and elastin (Park & Lakatta, 2012). 
 Renal failure model is a well-established model of reactive oxygen species, 
and it has been reported that increased oxidative stress also plays a role in arterial 
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elasticity. Oxidative injury may lead to vascular inflammation and increase cell 
cellular proliferation, which may subsequently lead to impaired arterial elasticity 
(Csiszar et al., 2002; Park & Lakatta, 2012).  
Arterial stiffening in renal disease is also driven by accumulation of calcium 
crystals (arterial calcification) within the internal wall of artery (Bazan et al., 2007). 
It has been also reported that several genes and molecules are associated with 
vascular wall stiffening (Laurent et al., 2005). Structural and cellular components 
take part in development of arterial stiffness as shown in Figure 1.3 
 
Figure ‎1.3: Summary of the causes of arterial aging adapted from (Lee & Oh, 
2010) 
 
Vascular changes have been affected by hemodynamic forces (Wolinsky & 
Glagov, 1969) and some extrinsic factors like hormones, salts and glucose 
metabolism and regulations. Some pathological states like hypertension, diabetes, 
metabolic disorders or simply aging can cause vascular changes which increase the 
arterial stiffness by different mechanisms. 
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The stability and compliance of blood vessels depends upon the functional 
contribution and stability of its two components, elastin and collagen. The 
concentration of both components determines the functional capacity of blood 
vessels. Any turnover in the concentration of both may shift blood vessel and lead to 
not only poor conduction of blood, but also many pathological states. Deregulation 
of this balance due to involvement of inflammatory mediators leads to over 
production of collagen and reduces the production of elastin leading to increased 
arterial stiffness (Johnson et al., 2001).  
Hypertension also increases the collagen production (Xu et al., 2000) which 
will increase the stiffness. The intima of stiffened vessels show disoriented 
endothelial cells. Elastin is broken due to collagen deposition and infiltration of 
vascular smooth muscle cells (VSMC), mononuclear cells and macrophages. 
Cytokine levels, tumor growth factor (TGF)-β, intracellular cell adhesion molecules 
and matrix metalloproteinase are increased (Lakatta & Levy, 2003). Therefore, 
inflammatory mediators are also responsible for increased arterial stiffness. 
Therapeutic agents which maintain the balance between elastin and collagen and 
inhibit these inflammatory mediators can be used in the treatment of arterial stiffness. 
1.3.3 Factors influencing arterial stiffness in renal insufficiency 
Arterial stiffness is increased in chronic cases of renal insufficiency. 
Increased arterial stiffness in renal insufficiency is due to involvement of several 
mechanisms, mainly extra pressure on intima wall, hypertension, and thickening of 
intima wall of blood vessels. Due to the activation of local and systemic renin 
angiotensin aldosterone system (RAAS), there is increased production of 
extracellular matrix metalloproteinase and VSMC proliferation. Arterial stiffness 
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in renal diseases is also initiated by diffused calcification without the involvement 
of inflammation and this histological picture is different from calcification in 
atherosclerotic plaque (Abedin et al., 2004; Goldsmith et al., 2004).  
1.4   Oxidative stress (OS) 
In the human body both oxidants and antioxidants are present and they 
mostly control the activities of each other. Compared to antioxidants, oxidative stress 
exists when oxidants are increased in our body. The net result is the increase in free 
radicals which ultimately cause damage to different organs of the body. This damage 
may play a significant role in the pathogenesis of different diseases. Oxidative stress 
plays a role in a number of diseases, like atherosclerosis, diabetes, inflammation and 
ischemia reperfusion injury (Griendling & Fitz Gerald, 2003; LeRoith et al., 2004).  
1.4.1 Reactive oxygen species  
Reactive oxygen species (ROS) are generally produced during normal 
cellular function. ROS includes hydroxyl radicals, superoxide anion, hydrogen 
peroxide and nitric oxide. Due to their high chemical reactivity, they lead to lipid 
peroxidation and oxidation of DNA and proteins of the cell. Under normal 
conditions, cellular antioxidant systems of the cell minimize the damage caused by 
ROS, however oxidative stress starts to develop when the level of ROS generation 
exceeds the level of cellular antioxidants (Valko et al., 2005). 
1.4.2 Reactive nitrogen species 
Reactive nitrogen species (RNS) are reactive metabolites of nitrogen (radical 
and non-radical). The most biologically reactive and important RNS are nitric oxide 
(NO
•
), peroxynitrite (ONOO
‾
) and nitrogen dioxide (NOO
•
). NO
•
 is a small molecule, 
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an important oxidative biological signalling molecule with one unpaired electron 
generated in biological tissues via nitric oxide synthases (NOSs). It has many vital 
physiological properties including neurotransmission, blood pressure regulation, 
defence mechanisms, smooth muscle relaxation and immune regulation (Bergendi et 
al., 1999). When NO
 
reacts with superoxide anion, it produces a potent oxidizing 
agent known as peroxynitrite anion, which plays a role in lipid oxidation and DNA 
fragmentation (Carr et al., 2000). 
1.5 Antioxidants 
Antioxidants prevent cell damage by inhibiting the oxidation of other 
molecules. They scavenge the free radicals which are highly reactive species 
responsible for cell damage and possessing major chance of various cardiovascular 
diseases. Multiple mechanisms are involved in the defence system of antioxidants. 
For example, superoxide dismutase scavenges superoxide and converts it to less 
reactive species. In patients with amyotrophic lateral sclerosis (ALS), also known as 
Lou Gehrig's disease, a defective gene for superoxide dismutase is found. This 
throws light on the existence of superoxide dismutase in biological systems, as well 
as other antioxidant enzymes like catalase and glutathione peroxidase, which 
suggests that oxidative damage can lead to cellular damage. Furthermore, apart from 
major antioxidant enzymes, several other small-molecule antioxidants (basically 
lipid-soluble and water-soluble antioxidants) also play important roles in antioxidant 
defence systems. The lipid-soluble antioxidants are localized to cellular membranes 
and lipoproteins, whereas the water-soluble antioxidants are present in aqueous 
fluids, such as blood and the fluids within cells and surrounding them. They are 
particularly important in blood and the fluids present in the extracellular space and 
generally become active in times when there is less availability of antioxidant 
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enzymes or when there is a total absence. A potential antioxidant should have the 
following capabilities: (i) Must be able to react with biologically active oxygen 
species (ii) the resultant pro-oxidant oxidant should not be more toxic than the 
metabolites removed from the body (iii) must be present in the body in sufficient 
quantity (iv) half of the antioxidant should be long enough to react with oxidants 
(Marklund, 1986). 
1.5.1 Enzymatic antioxidants 
Superoxide dismutase (SOD) is one of the important enzymatic antioxidants 
which play a significant role in the intracellular space. It helps in catalysis of 
superoxide radical to non-radical molecules O2 and H2O2. In humans there are three 
SOD isoforms (Cu/Zn SOD, Fe/Mn SOD and Ni SOD) (Richardson et al., 1975; 
Borgstahl et al., 1992 Barondeau et al., 2004) are known to be present. All the three 
isoforms of SOD catalyze dismutation of the superoxide. Depending on the site or 
tissue of origin, concentration of these enzymes differ (Marklund, 1986).  
Majority of aerobic organisms (except some bacteria and algae) commonly have 
catalase enzyme inside the body. It mainly catalyzes the decomposition of H2O2 to 
water and oxygen. In humans, it is present in every organ but is abundantly present in 
the liver and erythrocytes. 
2 H2O2 → 2H2O + O2 
The enzyme glutathione peroxidase plays a major role in the reduction of 
lipid hydro peroxides into their corresponding alcohols and free hydrogen peroxide 
to water. For the optimum physiological activity of GPx, sufficient concentration of 
GSH is required. Depending on the number of subunits in the selenium bond at the 
active centre, it is mainly found in two forms namely, selenium-dependent and 
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selenium-independent GPx. Selenium-dependent GPx is further composed of four 
subunits whereas selenium-independent GPx (glutathione-S-transferase, GST) 
catalysis detoxication of various xenobiotics (Holovska et al., 1998). 
1.5.2 Non-enzymatic antioxidants 
Glutathione (GSH) plays a very important role within the cells: organism 
protection from oxidative damage and detoxification processes. In the physiological 
environment, however, it is mostly present in the reduced form. Although it is a non-
enzymatic antioxidant, interestingly, it is also a cofactor for some antioxidant 
enzymes and hence participates in detoxication mechanisms by transferring amino 
acids through the cell membrane including glutathione peroxidase, glutathione 
transferase, and dehydroascorbate. Transferrin participates by inhibiting the 
formation of HO
• 
radical and lipid peroxidation and hence also acts as an antioxidant. 
It is a plasma protein binding Fe (III) atom. Lipid peroxidation cannot be catalyzing 
if transferrin is bound to iron ions (Aruoma & Halliwell, 1987). Another important 
extracellular antioxidant found in humans is ceruloplasmin, which is a Cu (II) 
transporting protein. Its specialty is that it can bind with all the plasma copper atoms. 
It also participates in the Fenton reaction and releases Fe (II) by changing its 
oxidative number. In the human extracellular space, antioxidant activity of 
ceruloplasmin is greatly contributed by albumin. An important function of serum 
albumin is to protect the hypochlorous acid (HOCl), produced by myeloperoxidase 
mediated oxidative damage (Ďuračková, 2008). This enzyme scavenges OH- radicals 
and oxygen (Ďuračková, 2008). GSH reverts Vitamin C and E into their active forms 
for their antioxidant actions. The ratio between GSH and its oxidized form is 
indicative of the redox state of the cell (Schafer & Buettner, 2001).  
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Vitamin E consists of a set of related compounds like α, β, γ and δ tocopherol. 
Among all these members, δ tocopherol being a fat soluble vitamin has the highest 
availability and antioxidant capability. Vitamin E scavenges or traps oxygen free 
radicals and inhibits the formation of chain reactions. Among these chain reactions 
tocopherol redical is propagated and can be reduced by ascorbate and glutathione to 
an active α tocopherol (Bast et al., 1991). 
Flavonoids being phenolic compounds are widely distributed in the plant 
kingdom. There are more than 4000 different derivatives isolated and the number of 
new isolated derivatives is increasing constantly. Quercetin and catechins are among 
flavonoids and are present in food as free monomers. Flavonoids may be bound to 
saccharides or glycosides. Several studies have endorsed the usefulness of flavonoid-
rich food in various diseases like coronary heart disease, myocardial infarction, 
cancer, neurodegenerative diseases, psychic diseases and other chronic diseases 
(Knekt et al., 2002; Trebaticka et al., 2006). 
Oxidative stress has been found to play a significant role in disease pathology. 
Some supplements containing flavonoids have been considered to exert therapeutic 
role in different diseases by their antioxidant mechanism.  
1.6 Vitamin C (Ascorbic acid) 
Vitamin C is used as ascorbic acid (reduced form) and dehydroascorbic acid 
(oxidized form). Vitamin C is one of the important water soluble vitamins that are 
present in plenty, in fresh fruits like orange, pineapple, raspberries, lemons, 
grapefruit, watermelon, papaya, strawberries, cantaloupe, mango, and cherries and in 
vegetables like broccoli ,tomato, cauliflower, cabbage, and green and red peppers. It 
is also present in feeds of plant origin that are relevant for animal nutrition, 
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particularly in green feeds and silages (Adikwu & Deo, 2013). Among nutrients, 
vitamin C which is an essential component in many fruits and vegetables like 
oranges, lemons and grapes, is widely used and consumed in our daily life. Vitamin 
C prevents the oxidation of other substrates by donating its electron. During this 
process, vitamin C is oxidized to a relatively stable radical known as ascorbyl. 
The average adult has a body pool of 1.2–2.0 g of ascorbic acid that may be 
preserved with 75 mg/dl of ascorbic acid. However, humans cannot synthesize 
ascorbic acid due to the absence of the enzyme L-gulonolactone oxidase. In humans, 
vitamin C is supplemented through food or as tablets. Vitamin C intake has been 
found to have a very profound effect in the reduction of cardiovascular disease risk 
(Mayne, 2003; May & Harrison, 2013). On the contrary, few studies have failed to 
see any effect of vitamin. C supplementation on the reduction of cardiovascular 
disease risk (Watanabe et al., 1998; Protogerou et al., 2002). It is a cofactor for 
several enzymes including the hydroxylation of proline, lysine essential for the 
synthesis of collagen; radical scavenger activity and NO-sparing function (May & 
Harrison, 2013). Supplements of vitamin C have achieved tremendous advantages as 
an antioxidant since it inhibits the genesis of atherosclerosis due to its effect on 
vascular remodelling, endothelial function, and lipid peroxidation.  
 Vitamin C is responsible for the synthesis of collagen. It also plays an important 
role in converting plasma iron into ferritin. It is important for neutrophil function, 
decreases circulating glucocorticoids and is also important for immune response. It 
also reduces oxidized tocopherol to its effective form in liver. Vitamin C is a dietary 
antioxidant which is used to prevent atherosclerosis. In atherosclerosis free radicals 
are involved at the early phase of endothelial dysfunction and in later phase of 
oxidation of the low-density lipoproteins (Korish & Arafah, 2008). It reduces the 
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adverse effects of ROS and RNS that can cause oxidative loss to macromolecules 
such as lipids, DNA and proteins, which are involved in cardiovascular disease, 
stroke, cancer, neurodegenerative diseases and cataractogenesis (Imam et al., 2011).  
 
 
 
Figure ‎1.4: Structure of vitamin C (ascorbic acid) adapted from Zümreoglu-
Karan, 2006 
 
1.7 Green tea polyphenol (GTPP) 
1.7.1 General description 
Tea is the most widely used drink in the world, second to water.  On the basis 
of the level of oxidation, tea can be divided into three types; Green tea, Oolong tea 
and black tea (Velayutham et al., 2008; Chan et al., 2011). All the three types 
originate from Camellia sinensis, but are treated differently to achieve different 
standards of oxidation. 
Green tea contains catechins in greater concentration than black and oolong 
tea. In vitro and in vivo, catechins are proven to be potentially strong antioxidants. In 
Chinese traditional medicines, since ancient times, green tea is considered as a 
healthy beverage. Green tea has some potential pharmacological properties such as 
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anti-hypertensive effect, body weight control, and antibacterial and antiviral activity. 
It is also used for solar ultraviolet protection, to increase bone mineral density and as 
neuroprotective. Green tea polyphenols also have anti-fibrotic action both on the 
arteries and skin. 
Certificate analysis of GTPP extract 95% are shown in the table 2.3 page 82 
which received from Nova Company. 
Polyphenols, especially flavanols and flavones, are available abundantly in 
green tea, which is nearly 30% dry weight of the fresh leaf (Balentine et al., 1997). 
Catechins are the most common flavones and fundamentally include (-) epicatechin 
(EC), (-) epicatechin-3-gallate (ECG), (-) epigallocatechin (EGC), (-) 
epigallocatechin-3-gallate (EGCG), (+) catechins and (+) gallocatechin (GC). 
EGCG, the most abundant catechin in green tea, accounts for about 65% of the total 
catechins content (Zaveri, 2006) as shown in the Figure 1.5. 
The exogenous administration of extract of green tea in rats was reported to 
increase the standard of the endogenous antioxidants such as glutathione peroxidase 
(GPx) and reductase, SOD and catalases. In vitro studies have shown that the 
epigallocatechin in green tea have angiotensin converting enzyme inhibitor 
properties (Actis-Goretta et al., 2006; Guerrero et al., 2012). Several studies 
conducted on animal models suggested that green tea lowers the blood pressure by 
reducing or suppressing the nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH oxidase) ROS in the vascular system. 
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Figure ‎1.5: Chemical structure of Epigallocatechin gallate in green tea adapted 
from Zaveri, 2006 
 
 
1.7.2 Polyphenols and vascular tone: Role of endothelial cells  
One of the major reasons for the progression of CVD is hypertension. Long 
standing high pressure and changes within the vascular walls may affect the heart, 
which can ultimately lead to cardiac failure. However, antioxidant consumption may 
have beneficial effect on the vascular tone. It is reported that drop in blood pressure 
and heart rate in hypertensive patients is markedly associated with increase in nitric 
oxide (NO) level after 30 minutes of polyphenol consumption (Matsuo et al., 2001). 
Similarly, red wine polyphenolic compounds (RWPC) were shown to possess 
hypotensive effect by inducing endothelium-dependent relaxation of the vessels of 
the aorta and mesenteric artery which are mainly associated with nitric oxide 
production (Fitzpatrick et al., 1993; Hodgson & Croft, 2006). There is well 
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documented evidence on the hypotensive activity of polyphenol from different 
sources like red wine, grape kin or an isolated polyphenol (quercetin). Interestingly, 
polyphenols fail to show its hypotensive effect when nitric oxide synthesis is 
chronically inhibited which suggests that its blood pressure lowering activity is 
mainly due to nitric oxide production. Similarly, another study showed that increased 
NO synthase activity helps to prevent L-nitro arginine-methyl ester-induced 
hypertension, cardiovascular remodelling and vascular dysfunction following red 
wine polyphenols. Studies have demonstrated that polyphenol extract and 
delphinidin (a major anthocyanin present in red wine), enhances the release of Ca
2++ 
  
which leads to NO release (Stoclet et al., 1999; Martin et al., 2002). This strongly 
suggests that polyphenol mediated NO production is mainly through an extracellular 
Ca
2+
 dependent mechanism in endothelial cells (Andriambeloson et al., 1999).  
Endothelial dysfunction may play a vital role in the development of CVD. 
Nitric oxide is a very potent mediator released from the endothelial cells which is an 
important regulator of vascular tone. When endothelium mediated NO release fails to 
cause sufficient vasodilatation of the blood vessels, it is known as endothelial 
dysfunction. It can be deduced that the antioxidant property of plant polyphenols 
plays a major role in the prevention of hypertension in experimental and clinical 
studies and can reduce the risk of CVD via activation of endothelial nitric oxide 
synthase (eNOS). 
1.7.3 Green tea and human health 
1.7.4 Green tea: Nutritional value 
Green tea consumption contributes to the overall daily fluid intake, while the 
calories intake is insignificant if sugar is avoided, and the caffeine intake is lower 
